There are currently 1270 clinical trials in Cleveland, Ohio looking for participants to engage in research studies. Trials are conducted at various facilities, including Cleveland Clinic, Cleveland Clinic Foundation, Case Western Reserve University and University Hospitals Cleveland Medical Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Non-interventional Study of Seroprevalence of Pre-existing Antibodies Against Adenovirus-associated Virus Vector (AAV9) and the Progression of Disease in Patients With Plakophilin 2 (PKP2)-Associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)
NCT06311708
Recruiting
This is a multicenter, non-interventional study to observe the natural progression of the disease and to study the prevalence of pre-existing antibodies to AAV9 used for gene therapy in a population of patients with PKP2 gene-associated ARVC. Participation from all patients is encouraged regardless of interest in or eligibility for gene therapy.
Gender:
ALL
Ages:
Between 14 years and 65 years
Trial Updated:
10/30/2024
Locations: Cleveland Clinic, Cleveland, Ohio
Conditions: Arrhythmogenic Right Ventricular Cardiomyopathy
Register for Updates
Developing Inclusive Support and Intervention for Spanish-speaking Latiné Prostate Cancer Survivors
NCT06435871
Recruiting
Prostate cancer is a significant concern for Latiné men, with over 17,000 new cases annually. Decision-making for treatment is complex, especially due to barriers like low health literacy and cultural factors. Research on survivorship and post-treatment issues like erectile dysfunction is lacking. To improve care, a study will engage 288 participants across various medical facilities, including 100 at Cleveland Clinic. Thirty subjects will participate in focus groups representing Spanish-speakin... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
10/30/2024
Locations: Cleveland Clinic Glickman Urological and Kidney Institute, Cleveland Clinic Foundation, Case Comprehensive Cancer Center, Cleveland, Ohio
Conditions: Prostate Cancer
Register for Updates
Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma
NCT05352672
Recruiting
This study is researching an experimental drug called REGN3767, also known as fianlimab (R3767), when combined with another medication called REGN2810, also known as cemiplimab (each individually called a "study drug" or called "study drugs" when combined). The study is focused on patients with a type of skin cancer known as melanoma. The aims of the study are to see how effective the combination of fianlimab and cemiplimab are in treating the melanoma skin cancer, in comparison with a medicati... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
10/28/2024
Locations: University Hospitals Seidmand Cancer Center, Cleveland, Ohio +1 locations
Conditions: Melanoma
Register for Updates
Natural History Study of Individuals With Autism and Germline Heterozygous PTEN Mutations
NCT02461446
Recruiting
The purpose of this study is to determine cross-sectional and longitudinal medical, behavioral, and cognitive differences between PTEN ASD and other groups, as well as to identify cognitive, neural systems, and molecular biomarkers specific to PTEN ASD. In addition, this study will be creating and maintaining a biorepository and linked phenotypic database for PTEN ASD.
Gender:
ALL
Ages:
18 months and above
Trial Updated:
10/24/2024
Locations: Cleveland Clinic, Cleveland, Ohio
Conditions: PTEN, ASD, Autism, Macrocephaly, PTEN Hamartoma Tumor Syndrome
Register for Updates
A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors
NCT04673942
Recruiting
AdAPT-001 is an oncolytic virus that is injected directly into the tumor or via intraarterial administration. The purpose of this study is to find out if AdAPT-001 is safe and tolerable. The next step is to find out if AdAPT-001 if efficacious with or without a checkpoint inhibitor.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/24/2024
Locations: Cleveland Clinic, Cleveland, Ohio
Conditions: Solid Tumor, Adult, Cancer, Neoplasms, Sarcoma, Sarcoma,Soft Tissue, Chondrosarcoma
Register for Updates
Phase I Trial to Evaluate VLP Peanut in Healthy and Peanut Allergic Subjects
NCT05476497
Recruiting
This phase I clinical trial is designed to evaluate the safety and tolerability of VLP Peanut in healthy subjects and in subjects with peanut allergy (PA). This clinical trial will evaluate the immunotoxicity profile of VLP Peanut in healthy subjects and assess the immunotoxicity profile and the degree of reactogenicity (allergenicity) in subjects with PA. This clinical trial will also explore preliminary proof of efficacy of VLP Peanut in subjects with PA.
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
10/24/2024
Locations: Cleveland Clinic Foundation, Cleveland, Ohio
Conditions: Peanut Allergy
Register for Updates
Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI
NCT05486572
Recruiting
The study is a randomized trial of two different screening methods for early detection of liver cancer in patients with cirrhosis of the liver. The goal of PREMIUM is to compare an abbreviated version of the diagnostic gold standard for HCC (aMRI) +AFP to the standard-of-care screening (US+AFP) in patients at high risk of developing HCC. The investigators hypothesize that HCC will be detected at earlier stages, allowing for more curative treatments and resulting in a reduction in HCC-related mor... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
10/24/2024
Locations: Louis Stokes VA Medical Center, Cleveland, OH, Cleveland, Ohio
Conditions: Carcinoma, Hepatocellular, Cirrhosis
Register for Updates
Trial of Therapeutic Hypothermia in Patients With ARDS
NCT04545424
Recruiting
Acute Respiratory Distress Syndrome (ARDS) is a serious condition that occurs as a complication of medical and surgical diseases, has a mortality of \~40%, and has no known treatment other than optimization of support. Data from basic research, animal models, and retrospective studies, case series, and small prospective studies suggest that therapeutic hypothermia (TH) similar to that used for cardiac arrest may be lung protective in patients with ARDS; however, shivering is a major complication... Read More
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
10/23/2024
Locations: Cleveland Clinc, Cleveland, Ohio
Conditions: Respiratory Distress Syndrome, Adult
Register for Updates
Connected Through Coaching for Flourishing Families
NCT06145451
Recruiting
Despite the known association between the quality of participant relational engagement with service providers and clinical outcomes, limited studies have examined caregiver Relational Responsiveness (RR) as a mechanism to achieve maltreatment prevention program outcomes. Using a realist-informed mixed method approach, this study will examine RR's role in mediating the effects of a community-based maltreatment prevention program, the Family Success Network (FSN) on protective factors against malt... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/18/2024
Locations: Case Western Reserve University, Cleveland, Ohio
Conditions: Maltreatment by Parent
Register for Updates
Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Non-Hodgkin Lymphoma
NCT05312801
Recruiting
Therapy with chimeric antigen receptor T (CAR-T) cells has demonstrated activity against refractory lymphoma, however not all tumors respond or remain in response to CD19 targeted CAR-T cells. We posit that CAR-T cells expressing BAFF (BAFF CAR-T cells) can become another strategy to treat refractory lymphoma, even after relapse following cluster of differentiation antigen 19 (CD19) targeting CAR-T treatment. This phase 1 study will evaluate safe dose and provide initial signal of the activity... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/16/2024
Locations: University Hospitals Seidman Cancer Center, Cleveland, Ohio +1 locations
Conditions: Lymphoma, Non-Hodgkin Lymphoma, B-Cell
Register for Updates
LMY-920 for Treatment of Relapsed or Refractory Myeloma
NCT05546723
Recruiting
Since CAR-T cell treatment of refractory myeloma has shown success, based on preclinical data, we posit that CAR-T cells expressing B-cell activating factor (BAFF) can become another strategy to treat refractory myeloma, even after relapse following BCMA targeting CAR-T cell treatment. This will be phase 1 study of BAFF ligand CAR-T cells in relapsed and refractory myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/16/2024
Locations: University Hospitals Seidman Cancer Center, Cleveland, Ohio
Conditions: Multiple Myeloma, Refractory, Multiple Myeloma in Relapse
Register for Updates
INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
NCT02977780
Recruiting
This research study is studying several investigational drugs as a possible treatment for Glioblastoma (GBM). The drugs involved in this study are : * Abemaciclib * Temozolomide (temodar) * Neratinib * CC115 * QBS10072S
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/15/2024
Locations: Cleveland Clinic, Cleveland, Ohio
Conditions: Glioblastoma
Register for Updates